ATE243514T1 - Verwendung von darifenacin zur verbesserung der wahrnehmung - Google Patents

Verwendung von darifenacin zur verbesserung der wahrnehmung

Info

Publication number
ATE243514T1
ATE243514T1 AT97303879T AT97303879T ATE243514T1 AT E243514 T1 ATE243514 T1 AT E243514T1 AT 97303879 T AT97303879 T AT 97303879T AT 97303879 T AT97303879 T AT 97303879T AT E243514 T1 ATE243514 T1 AT E243514T1
Authority
AT
Austria
Prior art keywords
darifenacin
improve perception
treatment
pharmaceutically acceptable
cognitive impairment
Prior art date
Application number
AT97303879T
Other languages
English (en)
Inventor
Michael John Allen
Brian Frank Johnson
Brian Robert Leaker
Robert Michael Wallis
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE243514T1 publication Critical patent/ATE243514T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007Acetylcholinesterase (3.1.1.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Control Of Eletrric Generators (AREA)
  • Soil Working Implements (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT97303879T 1996-06-18 1997-06-05 Verwendung von darifenacin zur verbesserung der wahrnehmung ATE243514T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9612710.5A GB9612710D0 (en) 1996-06-18 1996-06-18 Method of treatment

Publications (1)

Publication Number Publication Date
ATE243514T1 true ATE243514T1 (de) 2003-07-15

Family

ID=10795468

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97303879T ATE243514T1 (de) 1996-06-18 1997-06-05 Verwendung von darifenacin zur verbesserung der wahrnehmung

Country Status (15)

Country Link
US (1) US5837724A (de)
EP (1) EP0813870B1 (de)
JP (1) JP3453493B2 (de)
KR (1) KR980000445A (de)
AT (1) ATE243514T1 (de)
AU (1) AU2495697A (de)
CA (1) CA2208111C (de)
DE (1) DE69722999T2 (de)
DK (1) DK0813870T3 (de)
ES (1) ES2197972T3 (de)
GB (1) GB9612710D0 (de)
HU (1) HUP9701060A3 (de)
IL (1) IL121036A0 (de)
PT (1) PT813870E (de)
ZA (1) ZA975311B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7317102B2 (en) * 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
WO2009120277A1 (en) 2008-03-27 2009-10-01 Chase Pharmaceuticals Corporation Use and composition for treating dementia
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
ES2742728T3 (es) 2009-07-22 2020-02-17 PureTech Health LLC Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
ES2980131T3 (es) * 2017-06-01 2024-09-30 Eisai R&D Man Co Ltd Agente terapéutico para la demencia que combina derivado de pirazoloquinolina y donepezilo
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness

Also Published As

Publication number Publication date
US5837724A (en) 1998-11-17
ZA975311B (en) 1998-12-17
ES2197972T3 (es) 2004-01-16
HU9701060D0 (en) 1997-08-28
DE69722999T2 (de) 2003-12-18
DK0813870T3 (da) 2003-08-18
IL121036A0 (en) 1997-11-20
CA2208111A1 (en) 1997-12-18
HUP9701060A3 (en) 1999-03-29
EP0813870B1 (de) 2003-06-25
GB9612710D0 (en) 1996-08-21
DE69722999D1 (de) 2003-07-31
KR980000445A (ko) 1998-03-30
PT813870E (pt) 2003-10-31
AU2495697A (en) 1998-01-08
JP3453493B2 (ja) 2003-10-06
CA2208111C (en) 2002-10-15
HUP9701060A2 (hu) 1998-12-28
EP0813870A1 (de) 1997-12-29
JPH1059848A (ja) 1998-03-03

Similar Documents

Publication Publication Date Title
DE69729646D1 (de) Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv
DE69712003D1 (de) Modifikation von xylanase zur Verbesserung von Thermophilicität, alkophilicität und thermostabilität
DE69733329D1 (de) Verwendung von Taurin zur Behandlung oder Vorbeugung von ischämischen Verletzungen
DE69603734D1 (de) Blockcopolymere von Polyolefinen mit Polyurethanen, Copolyestern oder Copolyamiden und ihre Verwendung
DE69728771T2 (de) Herzschrittmacher mit treppensteigunterscheidung
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
ATE271393T1 (de) Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern
EA199800667A1 (ru) Новые фенантридины
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
PT936908E (pt) Derivados anticonvulsivos uteis no tratamento de esclerose lateral amiotrofica (ela)
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
GB9406857D0 (en) Improvements in or relating to organic compounds
DE69838728D1 (de) Methoden und zusammensetzungen zum wirksameren abfangen von sauerstoff
DE69526935D1 (de) Verwendung von mycobacterium zur tumorbehandlung
DE69733470D1 (de) Laserbearbeitung
DE69515070D1 (de) Zusammensetzung auf der Basis von alpha-Pyronen zur Induzierung und Stimulierung des Haarwachstums und/oder zur Verlangsamung des Haarausfalls und ihre Verwendung
DE69714736D1 (de) Polyaminen mit erhöhten nutzen für das aussehen von gewebe
ATE243514T1 (de) Verwendung von darifenacin zur verbesserung der wahrnehmung
DE69712578D1 (de) Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase
ATE227278T1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE69729768D1 (de) Herzschrittmacher mit Bestimmung des anaeroben Schwellwertes
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE69518438D1 (de) Behandlung von übereregten nervenzellenfunktionen
DE69709579D1 (de) System zur Überwachung von Biozidbehandlungen
DE59710757D1 (de) Verwendung von mikroporösem polyolefin zur absorption von schweiss und anderen körperausdünstungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0813870

Country of ref document: EP